CN Patent

CN116096886A — 用于调节叉头框p3(foxp3)基因表达的组合物和方法

Assigned to Omega Therapeutics Inc · Expires 2023-05-09 · 3y expired

What this patent protects

本发明提供用于通过靶向FOXP3表达控制区来调节叉头框P3(FOXP3)基因的表达(例如，增加或降低表达)的试剂和组合物，以及其用于治疗FOXP3相关病症(例如自身免疫性疾病，如IPEX综合征)的使用方法。

USPTO Abstract

本发明提供用于通过靶向FOXP3表达控制区来调节叉头框P3(FOXP3)基因的表达(例如，增加或降低表达)的试剂和组合物，以及其用于治疗FOXP3相关病症(例如自身免疫性疾病，如IPEX综合征)的使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116096886A
Jurisdiction
CN
Classification
—
Expires
2023-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Omega Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.